{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753153,0.00178147,0.00227994,0.0003637272,0.0003305751,0.0009581393,0.00083788,0.002071146,0.005738767],"category_scores_gemma":[0.002160263,0.0008675606,0.001584232,0.0003744978,0.001581891,0.001523786,0.0005098716,0.003133686,0.00101437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071718,"about_ca_system_score_gemma":0.0009633532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007091829,"about_ca_topic_score_gemma":0.001611583,"domain_scores_codex":[0.9993394,0.0003898284,0.00002745304,0.0001043741,0.00004291056,0.00009605695],"domain_scores_gemma":[0.9989781,0.0003371625,0.0001951616,0.00008698743,0.00003981611,0.0003627707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9806631,0.003770045,0.0006735985,0.0001791036,0.0003697191,0.00002758768,0.00005538426,0.0003106173,0.00253304,0.00006034163,0.0003911775,0.0109662],"study_design_scores_gemma":[0.875684,0.1199451,0.002348685,0.0000184444,0.0003468345,0.00005716455,0.00003092004,0.0003720478,0.0004540383,0.0001864646,0.0005392975,0.000017003],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950448,0.001832439,0.0002065504,0.000617025,0.000204571,0.000618451,0.0004117519,0.00004004815,0.001024329],"genre_scores_gemma":[0.9911761,0.001587286,0.0006657872,0.0008947636,0.0003255791,0.001336625,0.001083626,0.00002379462,0.002906492],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005738767,"threshold_uncertainty_score":0.01919806,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06039123479763487,"score_gpt":0.3881995916148677,"score_spread":0.3278083568172329,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}